Pulse Biosciences, Inc. (NASDAQ: PLSE) reported Q2 EPS of ($0.58), $0.17 better than the analyst estimate of ($0.75).

“We are pleased with the progress across the business in the second quarter. We onboarded a significant number of controlled launch participant clinics, including in Canada following the achievement of Health Canada approval for the CellFX System and continued to make progress on our clinical initiatives intended to broaden the CellFX System’s applications in aesthetic dermatology and beyond,” said Darrin Uecker, President and CEO of Pulse Biosciences. “With this progress and anticipated ongoing commercial conversions of controlled launch participants, we are well positioned to drive growth through increased adoption of CellFX procedures. We look forward to a broader commercial launch late in the year and toward delivering the benefits of NPS technology to more patients and clinicians.”

For earnings history and earnings-related data on Pulse Biosciences, Inc. (PLSE) click here.